Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .
Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
A multicenter double-blind r and omized study was carried out to compare the effect of timolol ( 10 mg twice daily ) with that of placebo in patients surviving acute myocardial infa rct ion . Treatment was started seven to 28 days after infa rct ion in 1884 patients ( 945 taking timolol , and 939 placebo ) , who represented 52 per cent of those evaluated for entry ; the patients were followed for 12 to 33 months ( mean , 17 ) . There were 152 deaths in the placebo group and 98 in the timolol group . When deaths that occurred during treatment or within 28 days of withdrawal were considered , the cumulated sudden-death rate over 33 months was 13.9 per cent in the placebo group and 7.7 per cent in the timolol group -- a reduction of 44.6 per cent ( P = 0.0001 ) . The cumulated reinfa rct ion rate was 20.1 per cent in the placebo group and 14.4 per cent in the timolol group ( P = 0.0006 ) . We conclude that long-term treatment with timolol in patients surviving acute myocardial infa rct ion reduces mortality and the rate of reinfa rct ion
Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .